All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Guardant Health, Pfizer win FDA approval for Guardant360 CDx companion diagnostic targeting BRAF V600E metastatic colorectal cancer
Small molecule, cancer, BRAF inhibitor, colorectal cancer, companion diagnostic, liquid biopsy - Read more

THE GOOD
Business Development & Partnerships

CEPI, Merck & Co., SK Bioscience collaborate on $30M improved Ebola vaccine manufacturing project
Research collaboration, infectious disease, vaccine, manufacturing, milestone payments - Read more

Bristol Myers Squibb, Janux Therapeutics partner on tumor-activated cancer drugs, $50M upfront, $850M total deal value
Co-development, oncology, T cell engager, milestone payments, tumor-activated therapy - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Corcept Therapeutics' relacorilant shows Ph3 overall survival benefit in platinum-resistant ovarian cancer
Small molecule, cancer, glucocorticoid receptor antagonist, ovarian cancer, combination therapy - Read more

Hoth Therapeutics reports positive Ph2 results for HT-001 targeting neurokinin 1 receptor in epidermal growth factor receptor inhibitor-induced skin toxicities
Small molecule, cancer, neurokinin 1 receptor agonist, EGFR inhibitor toxicity, dermatologic side effects - Read more

THE GOOD
Company Launches

BioMarin veterans launch Mendra with $82M Series A to use AI for rare disease drug development
Rare disease, strategic, investment, operational - Read more

Resolve M Therapeutics exits stealth with J&J-backed platform targeting inflammatory diseases through pro-resolution approach
Cell therapy, autoimmune, strategic, early-stage investment - Read more

THE GOOD
Earnings & Finances

Samsung Biologics becomes first Korean biopharma to surpass 2 trillion won ($1.36B) profit threshold in 2025
Contract manufacturing, strategic, major transaction, operational - Read more

THE GOOD
Fundraises

Corxel Pharmaceuticals raises $287M Series D1, obesity pill development and testing
Obesity, small molecule, GLP-1, clinical-stage - Read more

PAQ Therapeutics raises $77M Series B extension for KRAS-driven cancer therapies
Oncology, targeted protein degradation, KRAS-driven cancers, clinical-stage - Read more

Erasca raises $225M public offering, precision oncology for RAS/MAPK pathway cancers
Precision oncology, clinical-stage, cancer, RAS/MAPK pathway - Read more

THE GOOD
Lawsuits

Arbitration tribunal upholds Ipsen's termination of R&D agreement with Galderma, confirming toxin program rights
Recombinant protein, aesthetic medicine, strategic, regulatory - Read more

THE GOOD
Market Reports

Global pharma manufacturing output surged 9.1% in 2025 due to US tariff threat front-loading activities
Manufacturing, trade policy, operational, financial - Read more

THE GOOD
Regulatory

Lexicon Pharmaceuticals gets FDA clearance to advance non-opioid pain pill pilavapadin into Phase III trials
Small molecule, neurological, strategic, major transaction - Read more

THE GOOD
Strategic Plans

Sandoz eyes $322B biosimilar opportunity as 50+ biologics lose patent protection in golden decade ahead
Biosimilar, strategic, financial, competitive - Read more

Jaguar Health focuses on rare intestinal failure diseases using non-dilutive funds from Mytesi license deal closure
Small molecule, rare disease, strategic, major transaction - Read more

Hua Medicine plans expansion of diabetes drug Dorzagliatin beyond China into Asia markets
Small molecule, metabolic, strategic, competitive - Read more [Paywall]

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Politics & Policy

French presidency refutes Trump's Davos claims about Macron raising drug prices under tariff threats
Pharmaceutical pricing, regulatory, strategic, operational - Read more

THE BAD
Regulatory

NIH reinstates full ban on aborted fetal tissue research, affecting 77 funded projects across cancer and disease studies
Fetal tissue research, oncology, regulatory, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here